dan 2163 has been researched along with celecoxib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Dehning, S; Klauss, V; Krause, D; Möller, HJ; Müller, N; Musil, R; Obermeier, M; Riedel, M; Schennach-Wolff, R; Schwarz, MJ | 1 |
1 trial(s) available for dan 2163 and celecoxib
| Article | Year |
|---|---|
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.
Topics: Adult; Amisulpride; Celecoxib; Cyclooxygenase 2 Inhibitors; Dopamine Antagonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Female; Humans; Male; Psychiatric Status Rating Scales; Pyrazoles; Schizophrenia; Sulfonamides; Sulpiride; Time Factors; Treatment Outcome; Young Adult | 2010 |
1 other study(ies) available for dan 2163 and celecoxib
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |